Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai, UAE
Novartis’ ofatumumab (OMB157) has achieved the primary endpoints in two phase III trials of relapsing multiple sclerosis (MS).
Celgene Corporation has announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001.
VBI Vaccines has announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system.
Roche announced that its lung cancer drug Tecentriq (atezolizumab) has significantly improved overall survival (OS) rate in the phase III IMpower110 study.
Merck announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
Janssen Pharmaceutical said that the esketamine nasal spray along with the comprehensive standard of care (SOC) has met the primary efficacy endpoints of two phase 3 trials featuring adult patients with a major depressive disorder.
AstraZeneca announced that its Imfinzi (durvalumab) has significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC) in the phase III Caspian study.
Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use, long-term safety and tolerability of INP104 for the treatment of acute migraine.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.